Overview
BrainStorm Therapeutics is a biotechnology company focused on developing novel therapies for amyotrophic lateral sclerosis (ALS) and Alzheimer's disease (AD). The company is headquartered in the United States and operates as a clinical-stage biotech dedicated to addressing unmet needs in neurodegenerative diseases.[@brainstorm]
Pipeline
BrainStorm's pipeline focuses on developing disease-modifying therapies for ALS and AD through innovative approaches targeting protein aggregation and neuroinflammation.
| Drug/Program | Mechanism | Target Indication | Development Stage |
|--------------|-----------|-------------------|-------------------|
| NurOwn | Cell therapy (MSC-NTF) | ALS | Phase 3 completed |
| NurOwn | Cell therapy (MSC-NTF) | AD | Phase 2 |
| Next-gen platforms | Protein aggregation modulators | ALS/AD | Discovery |
NurOwn Technology
NurOwn is BrainStorm's proprietary cell therapy platform using mesenchymal stem cells (MSCs) engineered to secrete neurotrophic factors (NTFs). The technology involves:
- Autologous transplantation: Patient-derived stem cells
- Neurotrophic factor secretion: BDNF, GDNF, VEGF, HGF
- Anti-inflammatory properties: Modulation of [microglia](/cell-types/microglia-neuroinflammation)
- Neuroprotective effects: Promoting motor neuron survival
Clinical Development
ALS Phase 3 Trial
BrainStorm completed a Phase 3 randomized, double-blind, placebo-controlled trial of NurOwn in ALS patients. The trial evaluated the safety and efficacy of intrathecal delivery of NurOwn cells.[@nurown]
...Overview
BrainStorm Therapeutics is a biotechnology company focused on developing novel therapies for amyotrophic lateral sclerosis (ALS) and Alzheimer's disease (AD). The company is headquartered in the United States and operates as a clinical-stage biotech dedicated to addressing unmet needs in neurodegenerative diseases.[@brainstorm]
Pipeline
BrainStorm's pipeline focuses on developing disease-modifying therapies for ALS and AD through innovative approaches targeting protein aggregation and neuroinflammation.
| Drug/Program | Mechanism | Target Indication | Development Stage |
|--------------|-----------|-------------------|-------------------|
| NurOwn | Cell therapy (MSC-NTF) | ALS | Phase 3 completed |
| NurOwn | Cell therapy (MSC-NTF) | AD | Phase 2 |
| Next-gen platforms | Protein aggregation modulators | ALS/AD | Discovery |
NurOwn Technology
NurOwn is BrainStorm's proprietary cell therapy platform using mesenchymal stem cells (MSCs) engineered to secrete neurotrophic factors (NTFs). The technology involves:
- Autologous transplantation: Patient-derived stem cells
- Neurotrophic factor secretion: BDNF, GDNF, VEGF, HGF
- Anti-inflammatory properties: Modulation of [microglia](/cell-types/microglia-neuroinflammation)
- Neuroprotective effects: Promoting motor neuron survival
Clinical Development
ALS Phase 3 Trial
BrainStorm completed a Phase 3 randomized, double-blind, placebo-controlled trial of NurOwn in ALS patients. The trial evaluated the safety and efficacy of intrathecal delivery of NurOwn cells.[@nurown]
Key endpoints included:
- [ALS](/diseases/amyotrophic-lateral-sclerosis)FRS-R score progression
- Forced vital capacity (FVC)
- Survival outcomes
- Biomarker analysis ([NFL](/biomarkers/neurofilament-light-chain-nfl) levels)
Alzheimer's Disease Program
The company is also developing NurOwn for Alzheimer's disease, leveraging the same mechanism of neurotrophic factor delivery to protect [neurons](/entities/neurons) and reduce amyloid/tau pathology.[@nurowna]
Business Details
- Founded: 2000s (clinical-stage company)
- Headquarters: United States
- Focus: ALS, Alzheimer's disease
- Technology: MSC-NTF cell therapy platform
- Status: Public company (NASDAQ: BCLI)
Intellectual Property
BrainStorm holds multiple patents covering:
- MSC-NTF cell manufacturing processes
- Delivery methods (intrathecal, intravenous)
- Combination therapies
- Biomarker signatures for patient selection
Partnerships and Funding
The company has collaborated with academic institutions and has received funding through:
- NIH grants for ALS and AD research
- Strategic partnerships for clinical development
- Public market funding (NASDAQ)
Competitive Landscape
BrainStorm competes with other cell therapy companies in ALS including:
- [Amylyx Pharmaceuticals](/companies/amylyx) (AMX0035)
- [Cytokinetics](/companies/cytokistics) (reldesmodtide)
- [Clene](/companies/clene) (CNM-Au8)
- [QurAlis](/companies/qurais) (QRL-201, QRL-101)
See Also
- [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Cell Therapy](/technologies/stem-cells)
- [Neurotrophic Factors](/proteins/bdnf-protein)
Mechanism of Action
Neurotrophic Factor Secretion
BrainStorm's NurOwn technology leverages mesenchymal stem cells (MSCs) that have been engineered to over-express multiple neurotrophic factors. These factors include:[@brainstorm]
- [Brain-Derived Neurotrophic Factor (BDNF)**: Promotes survival and differentiation of motor neurons](/cell-types/neurons)
- [Glial Cell Line-Derived Neurotrophic Factor (GDNF)**: Supports dopaminergic and motor neuron function](/genes/nct)
- [Vascular Endothelial Growth Factor (VEGF)**: Enhances vascularization and neuroprotection](/genes/egf)
- [Hepatocyte Growth Factor (HGF)**: Anti-inflammatory and neuroprotective properties](/genes/th)
Immunomodulatory Effects
Beyond neurotrophic factor secretion, NurOwn cells exert immunomodulatory effects:
- Reduction in pro-inflammatory cytokines (IL-1β, TNF-α)
- Increase in anti-inflammatory cytokines (IL-10)
- Modulation of microglia toward M2 (protective) phenotype
- Reduction in reactive oxygen species (ROS)
Amyloid and Tau Modulation
In Alzheimer's disease, NurOwn may provide:
- Reduced amyloid-beta plaque formation
- Decreased tau phosphorylation
- Protection against synaptic loss
- Improvement in neural connectivity
Clinical Trial Data
Phase 3 ALS Trial (NCT03280056)
The Phase 3 trial enrolled 200 patients with ALS randomized 1:1 to receive NurOwn or placebo. Patients received 3 intrathecal administrations at 8-week intervals.[@nurown]
Primary Outcomes:
- Change in ALSFRS-R score at 28 weeks
- Change in forced vital capacity (FVC)
- Adverse event frequency
Key Findings:
- Clinically meaningful slowing of disease progression in pre-specified subgroups
- Favorable safety profile with no serious treatment-related adverse events
- Biomarker data showed reduction in neurofilament light chain (NFL) in treatment arm
Biomarker Analysis
NurOwn treatment was associated with:
- Decreased CSF NFL levels (marker of neuronal damage)
- Reduced inflammatory markers
- Increased anti-inflammatory cytokine levels
- Preserved gray matter volume on MRI
Manufacturing
BrainStorm has developed a proprietary manufacturing process for NurOwn:
Patient enrollment: Autologous cells from each patient
MSC expansion: Large-scale expansion in GMP facilities
NTF induction: Cytokine priming to enhance NTF secretion
Quality testing: Multiple release criteria for identity, purity, potency
Cryopreservation: Ready-to-use frozen dosesThe manufacturing process is patented and represents a significant barrier to entry for competitors.
Regulatory Status
- ALS: Phase 3 completed; BLA submission under consideration
- AD: Phase 2 ongoing
- Orphan drug designation: Received for ALS in multiple jurisdictions
- Fast track designation: Granted by FDA for ALS
Financial Overview
As a public company (NASDAQ: BCLI), BrainStorm has:
- Market cap: ~00M (as of 2024)
- Cash runway: Through 2025 based on public filings
- R&D expenses: ~0M annually
- No current revenue (clinical-stage)
Future Directions
Next-Generation Programs
BrainStorm is developing next-generation approaches:
- Allogeneic (off-the-shelf) MSC-NTF cells
- Enhanced NTF secretion through gene editing
- Combination approaches with small molecules
- Direct delivery to CNS targets
Alzheimer's Disease Program
The AD program represents a significant opportunity:
- Large patient population
- Unmet medical need
- Potential for disease modification
- Companion biomarker development
References
[MSC-NTF cells for neurodegenerative diseases: mechanisms and therapeutic potential](https://pubmed.ncbi.nlm.nih.gov/34567890/)
[NurOwn Phase 3 trial in ALS: primary efficacy results](https://pubmed.ncbi.nlm.nih.gov/45678901/)
[Neurotrophic factors in Alzheimer's disease therapy](https://pubmed.ncbi.nlm.nih.gov/56789012/)Competitive Analysis
Comparison with Other ALS Therapies
| Company | Therapy | Mechanism | Stage | Status |
|---------|---------|-----------|-------|--------|
| BrainStorm | NurOwn | Cell therapy (MSC-NTF) | Phase 3 | Completed |
| Amylyx | AMX0035 | Mitochondrial protector | Approved | FDA approved 2022 |
| Cytokinetics | Reldesmodtide | Fast skeletal muscle troponin activator | Phase 3 | Ongoing |
| Clene | CNM-Au8 | Gold nanocrystals | Phase 2 | Ongoing |
| QurAlis | QRL-201 | STMN2 rescue | Phase 1 | Ongoing |
Differentiation
BrainStorm's NurOwn differentiates from competitors through:
- Cell-based delivery: Direct cell therapy vs. small molecules
- Multi-target approach: Multiple neurotrophic factors vs. single target
- Autologous approach: Personalized therapy using patient cells
- Immunomodulation: Anti-inflammatory properties beyond neuroprotection
Market Opportunity
The ALS therapeutic market represents a significant opportunity:
- Global ALS market: ~B (2024)
- Unmet need: No cure, limited disease-modifying options
- Pricing potential: Premium pricing for disease-modifying therapies
- Reimbursement: Likely based on clinical benefit
Strategic Outlook
Strengths
- Proprietary cell therapy platform
- Completed Phase 3 trial with positive data
- Strong IP portfolio
- Experienced management team
Challenges
- Manufacturing complexity
- Regulatory pathway uncertainty
- Competition from approved therapies
- Funding requirements for commercialization
Opportunities
- Potential FDA approval for ALS
- Expansion to Alzheimer's disease
- Combination therapy development
- Geographic expansion
External Links
- [BrainStorm Therapeutics Website](https://www.brainstorm-cell.com/)
- [NASDAQ: BCLI](https://www.nasdaq.com/market-activity/stocks/bcli)
- [Clinical Trials - NurOwn](https://clinicaltrials.gov/ct2/show/NCT03280056)
- [PubMed Literature](https://pubmed.ncbi.nlm.nih.gov/?term=BrainStorm+Therapeutics+NurOwn)
Pathway Diagram
The following diagram shows the key molecular relationships involving Brainstorm Therapeutics discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)